Abstract
Simvastatin, is a lipid regulating drug, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), obtained by synthesis from lovastatin. It is indicated in the treatment of hyperlipidemias, including hypercholesterolaemias, combined mixed hyperlipidemia hyperlipoproteinemias, hypertriglyceridemia, and primary dysbetalipoproteinemia. This review describes a brief overview of the chemistry including impurities and different synthetic schemes, pharmacokinetic, pharmacodynamic and adverse effect of simvastatin as well as the recent trends in drug–drug interaction studies of simvastatin with various drug categories such as antibacterials, anticoagulants, antidepressants, antifungals, antivirals, calcium-channel blockers, immunosuppressants, lipid regulating drugs and grapefruit juice. This review also focuses distinctly on comprehensive update of various analytical methods for the quantification of simvastatin and/or its metabolites, impurities, degradants and other drugs.
Keywords: Analytical methods, impurities, pharmacodynamics, pharmacokinetics and simvastatin, hypercholesterolaemias, immunosuppressants, degradants, antifungals, antidepressants
Current Pharmaceutical Analysis
Title:Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Volume: 8 Issue: 2
Author(s): Pawan Kumar Basniwal and Deepti Jain
Affiliation:
Keywords: Analytical methods, impurities, pharmacodynamics, pharmacokinetics and simvastatin, hypercholesterolaemias, immunosuppressants, degradants, antifungals, antidepressants
Abstract: Simvastatin, is a lipid regulating drug, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), obtained by synthesis from lovastatin. It is indicated in the treatment of hyperlipidemias, including hypercholesterolaemias, combined mixed hyperlipidemia hyperlipoproteinemias, hypertriglyceridemia, and primary dysbetalipoproteinemia. This review describes a brief overview of the chemistry including impurities and different synthetic schemes, pharmacokinetic, pharmacodynamic and adverse effect of simvastatin as well as the recent trends in drug–drug interaction studies of simvastatin with various drug categories such as antibacterials, anticoagulants, antidepressants, antifungals, antivirals, calcium-channel blockers, immunosuppressants, lipid regulating drugs and grapefruit juice. This review also focuses distinctly on comprehensive update of various analytical methods for the quantification of simvastatin and/or its metabolites, impurities, degradants and other drugs.
Export Options
About this article
Cite this article as:
Kumar Basniwal Pawan and Jain Deepti, Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods, Current Pharmaceutical Analysis 2012; 8 (2) . https://dx.doi.org/10.2174/1573412911208020135
DOI https://dx.doi.org/10.2174/1573412911208020135 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Current Pharmaceutical Design A Cell Culture Model for the Assessment of the Chemopreventive Potential of Dietary Compounds.
Current Nutrition & Food Science Patent Selections
Recent Patents on Cardiovascular Drug Discovery Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Antioxidant Activity of Resveratrol Analogs
Letters in Drug Design & Discovery Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design 10 Years of SELDI: What Have we Learnt?
Current Proteomics Use of Chou’s 5-steps Rule to Study the Effect of Cereal Dietary Protein on Liver and Coronary Heart Disease Prevention
Current Nutrition & Food Science Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Current Alzheimer Research Selenium, an Ambivalent Factor in Diabetes? Established Facts, Recent Findings and Perspectives
Current Nutrition & Food Science Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Editorial: Paving the Way for Improved Antiplatelet Therapy
Current Pharmaceutical Design Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Fluoroquinolones: Blessings Or Curses
Current Drug Targets A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy